Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850525 | 1.00 | KMT2A (0.62) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL1310612 | 0.84 | SMN1; SMN2 (0.62) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL22193759 | 0.84 | LMNA (0.61) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL31673315 | 0.82 | SMN1; SMN2 (0.55) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL24846182 | 0.82 | KMT2A (0.52) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL4593418 | 0.82 | KMT2A (0.66) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL20668101 | 0.81 | MAPK1 (0.66) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL31673332 | 0.81 | MAPK1 (0.66) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL31673100 | 0.81 | SMN1; SMN2 (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL6857798 | 0.81 | SMN1; SMN2 (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
| US-20240174684-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC | 2024-05-30 | — | — | US | disclosed |
| WO-2024035622-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024035622-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4291188-A1 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | Bellbrook Labs, Llc (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116997339-A | Inhibitors of cGAS activity as therapeutic agents | 贝尔布鲁克实验室有限责任公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20220117968-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| US-20220117968-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| US-20220073532-A1 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC | 2022-03-10 | — | — | US | disclosed |
| EP-3906241-A1 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | Bellbrook Labs, Llc (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113302194-A | Inhibitors of cGAS activity as therapeutic agents | 贝尔布鲁克实验室有限责任公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020142729-A1 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | BellBrook Labs (US) | 2020-07-09 | — | — | WO | disclosed |
| EP-3565810-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-11-13 | — | — | EP | disclosed |
| WO-2019018359-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018359-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018127801-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-8552018-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2013-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174684-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | CGAS, STING1, IRF3 | KMT2A 3981/4885MEN1 3914/4885ALDH1A1 4232/4885 |
| US-20220117968-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | TYMS, DPYD, UMPS | KMT2A 3758/4885MEN1 4593/4885ALDH1A1 924/4885 |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | CGAS, SSB, FPGS | KMT2A 2247/4885MEN1 2128/4885ALDH1A1 1529/4885 |
| US-20220073532-A1 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | CGAS, STING1, IRF3 | KMT2A 3981/4885MEN1 3914/4885ALDH1A1 4232/4885 |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | KMT2A 4804/4885MEN1 2956/4885ALDH1A1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.